Targeting a specific receptor to improve treatment for ovarian cancer
Targeting ovarian cancer spheroid formation and metabolic adaptation by APJ inhibition
This study is looking at a type of ovarian cancer that can be tough to treat, and it’s exploring how blocking a specific receptor in the cancer cells might help make current treatments work better and stop the cancer from spreading.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11000765 on NIH RePORTER |
What this research studies
This research focuses on high-grade serous ovarian cancer, which is the most common and deadly form of ovarian cancer. It investigates how tumor cells form multicellular spheroids that help them survive and resist chemotherapy. The study aims to inhibit a specific receptor, known as APJ, which is involved in the cancer's ability to adapt and spread. By blocking this receptor, the researchers hope to enhance the effectiveness of existing treatments and reduce the cancer's ability to metastasize.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high-grade serous ovarian cancer, particularly those experiencing treatment resistance.
Not a fit: Patients with other types of ovarian cancer or those who are not currently undergoing treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for ovarian cancer, potentially improving survival rates for patients.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Woo, Sukyung — State University of New York at Buffalo
- Study coordinator: Woo, Sukyung
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.